Milestones
05 FEB 2004
Medigard lists on ASX at 135% premium. A$3.4m raised.
23 JUL 2004
Medigard receives Queensland Industry Development Scheme (QIDS) grant from the State Government.
26 APR 2005
Medigard receives Australian Design Award for its Blood Collection Device (BCD).
02 AUG 2005
Medigard receives second QIDS grant.
09 JUL 2008
Medigard appoints Genomic Research Centre (GRC), Griffith University, to perform simulated clinical trials on BCD.
27 AUG 2008
Simulated clinical trials are 100% successful and GRC praise Medigard for safety and ease of use.
24 SEP 2008
Grant of Australian patent for BCD.
19 JAN 2009
Approval granted by Food and Drug Administration (FDA) in US for BCD.
11 FEB 2009
Medigard announces Share Purchase Plan (SPP) and loyalty options.
10 MAR 2009
Product evaluations begin in major US hospitals.
02 APR 2009
SPP raises A$360,000 and Medigard issues 6,000,055 additional shares.
02 APR 2009
Issue of prospectus for 24,583,352 loyalty options free to all shareholders.
10 JUN 2009
Grant of US patent for BCD.
11 DEC 2009
Signing of MOU for manufacturing in the US.
26 MAY 2010
Manufacturing and distribution agreements signed.